Sanofi has reached US $2.3 billion cooperation with dice molecules

Source: Yigu 2016-03-18 Sanofi, the largest French pharmaceutical giant, announced on March 16 that it would sign a cooperation agreement of up to US $2.3 billion with dice molecules, a US unlisted pharmaceutical company, to jointly discover new oral drugs to replace injection therapy for some diseases Under a five-year cooperative research agreement, Sanofi will make an initial payment of $50 million, take a stake in dice and use the company's technology The two companies will then work together on up to 12 targeted drugs, each of which Sanofi will pay up to $184 million in research, clinical and regulatory milestones Sanofi will also pay a sales share to dice if any of the drugs are developed successfully Dice, headquartered in California, USA, specializes in the production of new tablets for the treatment of complex diseases that usually require injection of protein-based drugs Dice believes that its technology enables oral drugs to replace monoclonal antibodies that require injection or infusion Antibody drugs are used to treat many kinds of cancer, rheumatoid arthritis and other serious immune system diseases The technology also has the potential to solve the problem that there is no good treatment option "We hope this collaboration will lead to important therapies to tackle the current refractory diseases," said Kathy bowdish, director of sunrise initiative, which specializes in early stage drugs